Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

M L Baier1, G R Cutter, R A Rudick

  • 1Center for Research Methodology and Biometrics, Cooper Institute, 14023 Denver West Parkway, 100, Golden, CO 80401, USA. mbaier@denver.cooperinst.org

Neurology
|March 23, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2020
Same author

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

European journal of neurology·2019
Same author

Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.

European journal of neurology·2019
Same author

Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.

AJNR. American journal of neuroradiology·2019
Same author

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

AJNR. American journal of neuroradiology·2018
Same author

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

European journal of neurology·2018

Low-contrast letter acuity (L-CLA) testing shows strong validity for multiple sclerosis (MS) assessment. This visual test provides valuable insights into MS progression beyond the standard MS Functional Composite (MSFC).

Area of Science:

  • Ophthalmology
  • Neurology
  • Clinical Trials

Background:

  • Multiple Sclerosis (MS) significantly impacts visual function and overall health.
  • The Multiple Sclerosis Functional Composite (MSFC) is a standard tool for assessing MS progression.
  • Evaluating new visual tests for MS assessment is crucial for comprehensive patient monitoring.

Purpose of the Study:

  • To assess the concurrent and predictive validity of low-contrast letter acuity (L-CLA) testing.
  • To determine if L-CLA can serve as a valuable visual component for the MSFC.
  • To investigate the utility of L-CLA in capturing aspects of MS not fully measured by the MSFC.

Main Methods:

  • L-CLA testing was performed on two distinct MS patient cohorts (relapsing-remitting and secondary progressive MS).

Related Experiment Videos

  • Correlations were analyzed between L-CLA scores and established MS metrics like EDSS, MSFC, and brain parenchymal fraction (BPF).
  • Predictive validity was assessed by examining if L-CLA changes forecasted future changes in EDSS.

    • Main Results:

    • L-CLA scores demonstrated significant correlations with brain parenchymal fraction (BPF) and Expanded Disability Status Scale (EDSS).
    • L-CLA showed strong concurrent validity with the MSFC, indicating it measures similar aspects of MS.
    • Changes in L-CLA scores effectively predicted subsequent changes in EDSS, highlighting its predictive power.

    Conclusions:

    • Low-contrast letter acuity (L-CLA) testing possesses both concurrent and predictive validity in MS patients.
    • L-CLA provides unique information regarding the MS disease process not fully encompassed by the MSFC.
    • L-CLA is a promising candidate for inclusion in comprehensive MS assessment tools.